spacer
home > ebr > summer 2017 > editor’s letter
PUBLICATIONS
European Biopharmaceutical Review

Editor’s Letter

“It is important that rare disease businesses bring treatments to market as early as possible to give patients the best chance,” say Sobi’s Hege Hellström and Neil Dugdale in our summer 2017 industry Q&A. This captures the essence of therapy research and development for these often life-limiting illnesses affecting an estimated 70,000 patient groups. Access to the therapy, not just producing and commercialising it, should be a priority.

‘Salami-slicing’ of mass market, non-rare diseases to create artificial orphan indications is increasingly blurring lines between big pharma and specialised focus, according to The Weinberg Group’s Matthew Weinberg and Emily Krulewitz. Its driver is seemingly pharmacogenomics and the ability to stratify patients inside a group based on their genome and consequent response to particular therapies, switching them to personalised medicines.

Hermann Mascher at pharm-analyt Labor reminds us of the transformational potential these patient-specific therapeutics offer, and that particular biochemical pathways’ missing or defective components can be both the biomarker to identify a disease’s subset and the therapy to restore that deletion. If these could be characterised by bioanalytical methodologies serving a range of conditions, more synthetic forms of these endogenous small molecules may come on stream in development as therapeutics.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O’Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioGenes Establishes Scientific Advisory Board

Berlin, Germany, December 12, 2017 / B3C newswire / -- BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:
More info >>

White Papers

Bonfiglioli Engineering Headspace Gas Analysis Systems for Parenteral Manufacturing Processes: One Step Beyond Product Quality and Patient Safety

Bonfiglioli Engineering

This white paper presents the innovative solutions that Bonfiglioli Engineering has been developing in the field of HGA and their significant advantages over other existing systems.
More info >>

 
Industry Events

BioProcess International West

19-22 March 2018,

BioProcess International West (BPI West) is the leading phase-based bioprocessing event for advancing promising biologics towards commercial success.  Join 850+ global scientists and key decision makers at our upcoming meeting, held March 19-22, 2018 in San Francisco, CA. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement